All the news articles and press releases in one place.

Search
Date / Time Source Ticker Company Sector Market Cap Announcement
05May20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Clevegen manufacturing agreement
29Apr20 13:15 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
27Apr20 14:45 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
27Apr20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Traumakine to be a part of WHO’s Solidarity trial
23Apr20 13:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Update on results of Placing and issue of equity
22Apr20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Result of placing and issue price
21Apr20 16:45 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Proposed Placing
14Apr20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of Annual General Meeting
03Apr20 14:45 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m AGM to be postponed
01Apr20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m REMAP-CAP to study IFN beta-1a effect in COVID-19
30Mar20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Part 1 of the MATINS Phase I/II Study Completed
26Mar20 10:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Correction to Faron´s Annual Report 2019
25Mar20 07:28 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Faron´s Annual Report 2019 published
20Mar20 11:30 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of Annual General Meeting
20Mar20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Final Results for the year ended December 31, 2019
09Mar20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m FDA accepts protocol for new Traumakine trial
05Mar20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m MATINS update
02Mar20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Faron to acquire AOC3 antagonist platform
06Feb20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Traumakine update
27Jan20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Ovarian cancer selected as 2nd MATINS trial cohort
13Jan20 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m DMC approves colorectal cancer cohort expansion
30Dec19 09:30 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Update on Traumakine drug substance manufacturing
11Dec19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Matins Trial Update
29Nov19 07:31 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m LIQUIDITY PROVIDING AGREEMENT
29Nov19 07:30 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Company Description & information on cash position
28Nov19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m FDA has approved Faron's Clevegen IND
27Nov19 16:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Faron´s financial calendar for 2020
21Nov19 14:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holdings in Company
21Nov19 07:15 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Application to Nasdaq First North Growth Market
12Nov19 15:45 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Registration of Shares
08Nov19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Results of Placing and Issue Price
07Nov19 16:51 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Proposed Placing and Financial Adviser Appointment
01Nov19 14:15 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Statement regarding Price Movement
25Oct19 09:27 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Results of EGM
09Oct19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Matins Trial Update
04Oct19 07:20 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of EGM
02Oct19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Update on Traumakine drug substance manufacturing
30Sep19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m MATINS poster presentation at ESMO Congress
25Sep19 09:13 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holdings in Company
23Sep19 07:08 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Interim results
02Sep19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m MATINS study selected for ESMO 2019
27Aug19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Result of Open Offer and Further Subscription
19Aug19 09:33 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
16Aug19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of Interim Results
06Aug19 13:53 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Issue of Equity
05Aug19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Subscription and Open Offer
12Jul19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m MATINS study update
04Jul19 09:31 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holdings in Company
01Jul19 12:10 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Grant of options
26Jun19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Phase II INFORAAA study update
14Jun19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Final results from YODA study
28May19 12:27 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Results of AGM
24May19 09:32 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m AGM update, Board & management changes
22May19 12:51 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Grant of Options
21May19 09:21 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
16May19 09:16 RNS FARN:LON, AV:LON Aviva plc, Faron Pharmaceuticals Oy Various Various Holding(s) in Company
14May19 07:01 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holdings in Company
14May19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Share Subscription and Issue of Equity
07May19 07:05 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of AGM
07May19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Final Results for the year ended 31 December 2018
02May19 17:20 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Statement regarding Price Movement
29Apr19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Results from the Japanese Phase III study
25Apr19 16:09 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
12Apr19 13:20 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
11Apr19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m First expansion cohort for MATINS trial part 2
10Apr19 11:41 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
05Apr19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of Results
02Apr19 09:23 RNS FARN:LON, AV:LON Aviva plc, Faron Pharmaceuticals Oy Various Various Holdings in Company
29Mar19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
28Mar19 12:54 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Results of the Placing and Subscription
26Mar19 15:31 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Result of Placing and Issue Price
26Mar19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Proposed Placing to raise approximately EUR 3m
21Feb19 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m MATINS study update
13Feb19 08:57 RNS-R FARN:LON Faron Pharmaceuticals Oy Health £84.6m New data published by Clinical Cancer Research
19Dec18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Traumakine update - YODA results
14Dec18 11:20 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m First patient dosed in phase I/II MATINS study
11Dec18 16:26 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
05Dec18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Patient subgroup identified from INTEREST trial
03Dec18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Faron receives CTA approval for Clevegen
06Nov18 15:52 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m PDMR Dealings
22Oct18 15:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m INTEREST trial update presented at ESICM
18Sep18 09:23 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Director/PDMR Shareholding
17Sep18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Faron announces CTA filing for Clevegen
13Sep18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Interim Results
08Aug18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of Interim Results
09Jul18 08:45 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
22Jun18 07:00 RNS FARN:LON, LGEN:LON Faron Pharmaceuticals Oy, Legal & General Group Plc Various Various Holdings in Company
21Jun18 15:58 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Director/PDMR Shareholding
21Jun18 07:40 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Director/PDMR Shareholding
20Jun18 08:43 RNS FARN:LON, LGEN:LON Faron Pharmaceuticals Oy, Legal & General Group Plc Various Various Holding(s) in Company
18Jun18 15:42 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holdings in Company
14Jun18 07:00 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Biomarker analysis of Phase III INTEREST trial
31May18 14:33 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Result of AGM
16May18 17:53 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m PDMR Shareholding
15May18 15:14 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Director/PDMR Shareholding
15May18 13:16 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holdings in Company
11May18 16:51 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
11May18 13:37 RNS FARN:LON, LGEN:LON Faron Pharmaceuticals Oy, Legal & General Group Plc Various Various Holding(s) in Company
11May18 13:34 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Holding(s) in Company
10May18 10:05 RNS FARN:LON Faron Pharmaceuticals Oy Health £84.6m Notice of AGM
Date / Time Source Company % Chg
05May20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Clevegen manufacturing agreement
29Apr20 13:15 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
27Apr20 14:45 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
27Apr20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Traumakine to be a part of WHO’s Solidarity trial
23Apr20 13:00 RNS Faron Pharmaceuticals Oy -0.42%
Update on results of Placing and issue of equity
22Apr20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Result of placing and issue price
21Apr20 16:45 RNS Faron Pharmaceuticals Oy -0.42%
Proposed Placing
14Apr20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Notice of Annual General Meeting
03Apr20 14:45 RNS Faron Pharmaceuticals Oy -0.42%
AGM to be postponed
01Apr20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
REMAP-CAP to study IFN beta-1a effect in COVID-19
30Mar20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Part 1 of the MATINS Phase I/II Study Completed
26Mar20 10:00 RNS Faron Pharmaceuticals Oy -0.42%
Correction to Faron´s Annual Report 2019
25Mar20 07:28 RNS Faron Pharmaceuticals Oy -0.42%
Faron´s Annual Report 2019 published
20Mar20 11:30 RNS Faron Pharmaceuticals Oy -0.42%
Notice of Annual General Meeting
20Mar20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Final Results for the year ended December 31, 2019
09Mar20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
FDA accepts protocol for new Traumakine trial
05Mar20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
MATINS update
02Mar20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Faron to acquire AOC3 antagonist platform
06Feb20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Traumakine update
27Jan20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Ovarian cancer selected as 2nd MATINS trial cohort
13Jan20 07:00 RNS Faron Pharmaceuticals Oy -0.42%
DMC approves colorectal cancer cohort expansion
30Dec19 09:30 RNS Faron Pharmaceuticals Oy -0.42%
Update on Traumakine drug substance manufacturing
11Dec19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Matins Trial Update
29Nov19 07:31 RNS Faron Pharmaceuticals Oy -0.42%
LIQUIDITY PROVIDING AGREEMENT
29Nov19 07:30 RNS Faron Pharmaceuticals Oy -0.42%
Company Description & information on cash position
28Nov19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
FDA has approved Faron's Clevegen IND
27Nov19 16:00 RNS Faron Pharmaceuticals Oy -0.42%
Faron´s financial calendar for 2020
21Nov19 14:00 RNS Faron Pharmaceuticals Oy -0.42%
Holdings in Company
21Nov19 07:15 RNS Faron Pharmaceuticals Oy -0.42%
Application to Nasdaq First North Growth Market
12Nov19 15:45 RNS Faron Pharmaceuticals Oy -0.42%
Registration of Shares
08Nov19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Results of Placing and Issue Price
07Nov19 16:51 RNS Faron Pharmaceuticals Oy -0.42%
Proposed Placing and Financial Adviser Appointment
01Nov19 14:15 RNS Faron Pharmaceuticals Oy -0.42%
Statement regarding Price Movement
25Oct19 09:27 RNS Faron Pharmaceuticals Oy -0.42%
Results of EGM
09Oct19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Matins Trial Update
04Oct19 07:20 RNS Faron Pharmaceuticals Oy -0.42%
Notice of EGM
02Oct19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Update on Traumakine drug substance manufacturing
30Sep19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
MATINS poster presentation at ESMO Congress
25Sep19 09:13 RNS Faron Pharmaceuticals Oy -0.42%
Holdings in Company
23Sep19 07:08 RNS Faron Pharmaceuticals Oy -0.42%
Interim results
02Sep19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
MATINS study selected for ESMO 2019
27Aug19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Result of Open Offer and Further Subscription
19Aug19 09:33 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
16Aug19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Notice of Interim Results
06Aug19 13:53 RNS Faron Pharmaceuticals Oy -0.42%
Issue of Equity
05Aug19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Subscription and Open Offer
12Jul19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
MATINS study update
04Jul19 09:31 RNS Faron Pharmaceuticals Oy -0.42%
Holdings in Company
01Jul19 12:10 RNS Faron Pharmaceuticals Oy -0.42%
Grant of options
26Jun19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Phase II INFORAAA study update
14Jun19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Final results from YODA study
28May19 12:27 RNS Faron Pharmaceuticals Oy -0.42%
Results of AGM
24May19 09:32 RNS Faron Pharmaceuticals Oy -0.42%
AGM update, Board & management changes
22May19 12:51 RNS Faron Pharmaceuticals Oy -0.42%
Grant of Options
21May19 09:21 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
16May19 09:16 RNS Aviva plc, Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
14May19 07:01 RNS Faron Pharmaceuticals Oy -0.42%
Holdings in Company
14May19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Share Subscription and Issue of Equity
07May19 07:05 RNS Faron Pharmaceuticals Oy -0.42%
Notice of AGM
07May19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Final Results for the year ended 31 December 2018
02May19 17:20 RNS Faron Pharmaceuticals Oy -0.42%
Statement regarding Price Movement
29Apr19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Results from the Japanese Phase III study
25Apr19 16:09 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
12Apr19 13:20 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
11Apr19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
First expansion cohort for MATINS trial part 2
10Apr19 11:41 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
05Apr19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Notice of Results
02Apr19 09:23 RNS Aviva plc, Faron Pharmaceuticals Oy -0.42%
Holdings in Company
29Mar19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
28Mar19 12:54 RNS Faron Pharmaceuticals Oy -0.42%
Results of the Placing and Subscription
26Mar19 15:31 RNS Faron Pharmaceuticals Oy -0.42%
Result of Placing and Issue Price
26Mar19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Proposed Placing to raise approximately EUR 3m
21Feb19 07:00 RNS Faron Pharmaceuticals Oy -0.42%
MATINS study update
13Feb19 08:57 RNS-R Faron Pharmaceuticals Oy -0.42%
New data published by Clinical Cancer Research
19Dec18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Traumakine update - YODA results
14Dec18 11:20 RNS Faron Pharmaceuticals Oy -0.42%
First patient dosed in phase I/II MATINS study
11Dec18 16:26 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
05Dec18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Patient subgroup identified from INTEREST trial
03Dec18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Faron receives CTA approval for Clevegen
06Nov18 15:52 RNS Faron Pharmaceuticals Oy -0.42%
PDMR Dealings
22Oct18 15:00 RNS Faron Pharmaceuticals Oy -0.42%
INTEREST trial update presented at ESICM
18Sep18 09:23 RNS Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
17Sep18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Faron announces CTA filing for Clevegen
13Sep18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Interim Results
08Aug18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Notice of Interim Results
09Jul18 08:45 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
22Jun18 07:00 RNS Faron Pharmaceuticals Oy, Legal & General Group Plc -0.42%
Holdings in Company
21Jun18 15:58 RNS Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
21Jun18 07:40 RNS Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
20Jun18 08:43 RNS Faron Pharmaceuticals Oy, Legal & General Group Plc -0.42%
Holding(s) in Company
18Jun18 15:42 RNS Faron Pharmaceuticals Oy -0.42%
Holdings in Company
14Jun18 07:00 RNS Faron Pharmaceuticals Oy -0.42%
Biomarker analysis of Phase III INTEREST trial
31May18 14:33 RNS Faron Pharmaceuticals Oy -0.42%
Result of AGM
16May18 17:53 RNS Faron Pharmaceuticals Oy -0.42%
PDMR Shareholding
15May18 15:14 RNS Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
15May18 13:16 RNS Faron Pharmaceuticals Oy -0.42%
Holdings in Company
11May18 16:51 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
11May18 13:37 RNS Faron Pharmaceuticals Oy, Legal & General Group Plc -0.42%
Holding(s) in Company
11May18 13:34 RNS Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
10May18 10:05 RNS Faron Pharmaceuticals Oy -0.42%
Notice of AGM
Date / Time Company % Chg
05May20 07:00 Faron Pharmaceuticals Oy -0.42%
Clevegen manufacturing agreement
29Apr20 13:15 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
27Apr20 14:45 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
27Apr20 07:00 Faron Pharmaceuticals Oy -0.42%
Traumakine to be a part of WHO’s Solidarity trial
23Apr20 13:00 Faron Pharmaceuticals Oy -0.42%
Update on results of Placing and issue of equity
22Apr20 07:00 Faron Pharmaceuticals Oy -0.42%
Result of placing and issue price
21Apr20 16:45 Faron Pharmaceuticals Oy -0.42%
Proposed Placing
14Apr20 07:00 Faron Pharmaceuticals Oy -0.42%
Notice of Annual General Meeting
03Apr20 14:45 Faron Pharmaceuticals Oy -0.42%
AGM to be postponed
01Apr20 07:00 Faron Pharmaceuticals Oy -0.42%
REMAP-CAP to study IFN beta-1a effect in COVID-19
30Mar20 07:00 Faron Pharmaceuticals Oy -0.42%
Part 1 of the MATINS Phase I/II Study Completed
26Mar20 10:00 Faron Pharmaceuticals Oy -0.42%
Correction to Faron´s Annual Report 2019
25Mar20 07:28 Faron Pharmaceuticals Oy -0.42%
Faron´s Annual Report 2019 published
20Mar20 11:30 Faron Pharmaceuticals Oy -0.42%
Notice of Annual General Meeting
20Mar20 07:00 Faron Pharmaceuticals Oy -0.42%
Final Results for the year ended December 31, 2019
09Mar20 07:00 Faron Pharmaceuticals Oy -0.42%
FDA accepts protocol for new Traumakine trial
05Mar20 07:00 Faron Pharmaceuticals Oy -0.42%
MATINS update
02Mar20 07:00 Faron Pharmaceuticals Oy -0.42%
Faron to acquire AOC3 antagonist platform
06Feb20 07:00 Faron Pharmaceuticals Oy -0.42%
Traumakine update
27Jan20 07:00 Faron Pharmaceuticals Oy -0.42%
Ovarian cancer selected as 2nd MATINS trial cohort
13Jan20 07:00 Faron Pharmaceuticals Oy -0.42%
DMC approves colorectal cancer cohort expansion
30Dec19 09:30 Faron Pharmaceuticals Oy -0.42%
Update on Traumakine drug substance manufacturing
11Dec19 07:00 Faron Pharmaceuticals Oy -0.42%
Matins Trial Update
29Nov19 07:31 Faron Pharmaceuticals Oy -0.42%
LIQUIDITY PROVIDING AGREEMENT
29Nov19 07:30 Faron Pharmaceuticals Oy -0.42%
Company Description & information on cash position
28Nov19 07:00 Faron Pharmaceuticals Oy -0.42%
FDA has approved Faron's Clevegen IND
27Nov19 16:00 Faron Pharmaceuticals Oy -0.42%
Faron´s financial calendar for 2020
21Nov19 14:00 Faron Pharmaceuticals Oy -0.42%
Holdings in Company
21Nov19 07:15 Faron Pharmaceuticals Oy -0.42%
Application to Nasdaq First North Growth Market
12Nov19 15:45 Faron Pharmaceuticals Oy -0.42%
Registration of Shares
08Nov19 07:00 Faron Pharmaceuticals Oy -0.42%
Results of Placing and Issue Price
07Nov19 16:51 Faron Pharmaceuticals Oy -0.42%
Proposed Placing and Financial Adviser Appointment
01Nov19 14:15 Faron Pharmaceuticals Oy -0.42%
Statement regarding Price Movement
25Oct19 09:27 Faron Pharmaceuticals Oy -0.42%
Results of EGM
09Oct19 07:00 Faron Pharmaceuticals Oy -0.42%
Matins Trial Update
04Oct19 07:20 Faron Pharmaceuticals Oy -0.42%
Notice of EGM
02Oct19 07:00 Faron Pharmaceuticals Oy -0.42%
Update on Traumakine drug substance manufacturing
30Sep19 07:00 Faron Pharmaceuticals Oy -0.42%
MATINS poster presentation at ESMO Congress
25Sep19 09:13 Faron Pharmaceuticals Oy -0.42%
Holdings in Company
23Sep19 07:08 Faron Pharmaceuticals Oy -0.42%
Interim results
02Sep19 07:00 Faron Pharmaceuticals Oy -0.42%
MATINS study selected for ESMO 2019
27Aug19 07:00 Faron Pharmaceuticals Oy -0.42%
Result of Open Offer and Further Subscription
19Aug19 09:33 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
16Aug19 07:00 Faron Pharmaceuticals Oy -0.42%
Notice of Interim Results
06Aug19 13:53 Faron Pharmaceuticals Oy -0.42%
Issue of Equity
05Aug19 07:00 Faron Pharmaceuticals Oy -0.42%
Subscription and Open Offer
12Jul19 07:00 Faron Pharmaceuticals Oy -0.42%
MATINS study update
04Jul19 09:31 Faron Pharmaceuticals Oy -0.42%
Holdings in Company
01Jul19 12:10 Faron Pharmaceuticals Oy -0.42%
Grant of options
26Jun19 07:00 Faron Pharmaceuticals Oy -0.42%
Phase II INFORAAA study update
14Jun19 07:00 Faron Pharmaceuticals Oy -0.42%
Final results from YODA study
28May19 12:27 Faron Pharmaceuticals Oy -0.42%
Results of AGM
24May19 09:32 Faron Pharmaceuticals Oy -0.42%
AGM update, Board & management changes
22May19 12:51 Faron Pharmaceuticals Oy -0.42%
Grant of Options
21May19 09:21 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
16May19 09:16 AV. LSE,FARN LSE -0.42%
Holding(s) in Company
14May19 07:01 Faron Pharmaceuticals Oy -0.42%
Holdings in Company
14May19 07:00 Faron Pharmaceuticals Oy -0.42%
Share Subscription and Issue of Equity
07May19 07:05 Faron Pharmaceuticals Oy -0.42%
Notice of AGM
07May19 07:00 Faron Pharmaceuticals Oy -0.42%
Final Results for the year ended 31 December 2018
02May19 17:20 Faron Pharmaceuticals Oy -0.42%
Statement regarding Price Movement
29Apr19 07:00 Faron Pharmaceuticals Oy -0.42%
Results from the Japanese Phase III study
25Apr19 16:09 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
12Apr19 13:20 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
11Apr19 07:00 Faron Pharmaceuticals Oy -0.42%
First expansion cohort for MATINS trial part 2
10Apr19 11:41 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
05Apr19 07:00 Faron Pharmaceuticals Oy -0.42%
Notice of Results
02Apr19 09:23 AV. LSE,FARN LSE -0.42%
Holdings in Company
29Mar19 07:00 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
28Mar19 12:54 Faron Pharmaceuticals Oy -0.42%
Results of the Placing and Subscription
26Mar19 15:31 Faron Pharmaceuticals Oy -0.42%
Result of Placing and Issue Price
26Mar19 07:00 Faron Pharmaceuticals Oy -0.42%
Proposed Placing to raise approximately EUR 3m
21Feb19 07:00 Faron Pharmaceuticals Oy -0.42%
MATINS study update
13Feb19 08:57 Faron Pharmaceuticals Oy -0.42%
New data published by Clinical Cancer Research
19Dec18 07:00 Faron Pharmaceuticals Oy -0.42%
Traumakine update - YODA results
14Dec18 11:20 Faron Pharmaceuticals Oy -0.42%
First patient dosed in phase I/II MATINS study
11Dec18 16:26 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
05Dec18 07:00 Faron Pharmaceuticals Oy -0.42%
Patient subgroup identified from INTEREST trial
03Dec18 07:00 Faron Pharmaceuticals Oy -0.42%
Faron receives CTA approval for Clevegen
06Nov18 15:52 Faron Pharmaceuticals Oy -0.42%
PDMR Dealings
22Oct18 15:00 Faron Pharmaceuticals Oy -0.42%
INTEREST trial update presented at ESICM
18Sep18 09:23 Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
17Sep18 07:00 Faron Pharmaceuticals Oy -0.42%
Faron announces CTA filing for Clevegen
13Sep18 07:00 Faron Pharmaceuticals Oy -0.42%
Interim Results
08Aug18 07:00 Faron Pharmaceuticals Oy -0.42%
Notice of Interim Results
09Jul18 08:45 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
22Jun18 07:00 FARN LSE,LGEN LSE -0.42%
Holdings in Company
21Jun18 15:58 Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
21Jun18 07:40 Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
20Jun18 08:43 FARN LSE,LGEN LSE -0.42%
Holding(s) in Company
18Jun18 15:42 Faron Pharmaceuticals Oy -0.42%
Holdings in Company
14Jun18 07:00 Faron Pharmaceuticals Oy -0.42%
Biomarker analysis of Phase III INTEREST trial
31May18 14:33 Faron Pharmaceuticals Oy -0.42%
Result of AGM
16May18 17:53 Faron Pharmaceuticals Oy -0.42%
PDMR Shareholding
15May18 15:14 Faron Pharmaceuticals Oy -0.42%
Director/PDMR Shareholding
15May18 13:16 Faron Pharmaceuticals Oy -0.42%
Holdings in Company
11May18 16:51 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
11May18 13:37 FARN LSE,LGEN LSE -0.42%
Holding(s) in Company
11May18 13:34 Faron Pharmaceuticals Oy -0.42%
Holding(s) in Company
10May18 10:05 Faron Pharmaceuticals Oy -0.42%
Notice of AGM